



## Pharmaceutical Industry Fellowship Program 2024

Together  
We Discover

At argenx, we've created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side by side to propel the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.

**RUTGERS**  
Institute for Pharmaceutical  
Industry Fellowships

# Table of Contents

## About argenx

About argenx.....	3
Our Core Values .....	4
Our Pipeline.....	5
Our Fellowship Leadership.....	6
Medical Affairs Fellowship Position.....	7
Fellowship Breakdown .....	8

## Rutgers Institute for Pharmaceutical Industry Fellowships

Program History.....	9
Key Program Features.....	10
Professional Development Day Series.....	10
How to Apply .....	11

## About argenx

Dear prospective Fellow,

At argenx, we are committed to improving the lives of people suffering from severe autoimmune diseases. argenx was founded in 2008, based on a groundbreaking antibody engineering discovery and a philosophy that collaboration is key to success. It is with these foundational components that we created the Immunology Innovation Program (IIP), an innovation ecosystem that unites our antibody engineering expertise with the unique disease biology insights of our research collaborators, primarily in academia. Through this program, we look to propel the discovery of novel targets, disease pathways, and differentiated therapeutic antibodies, together elevating breakthrough research into potential new medicines—and the world is starting to notice, with Scrip calling argenx “one of the crown jewels of the European biotech sector.”

At argenx, the patient comes first; we’re striving to redefine immunology by operating at the intersection of breakthrough science and unmet clinical need. We believe that the patient journey is a critical aspect of treatment, and patient satisfaction and access to information are key. We are proud to have been named a finalist for the 2023 Biotech Week Boston Awards for Transformational Therapy. We also were nominated in 2022 for the prestigious Prix Galien award under the Best Biotechnology Product category. In 2022, we brought home the Fast Company Most Innovative Companies award and two PM360 Trailblazer awards (Persistence/Adherence Program and Autoimmune Brand Champion). Our documentary series “A Mystery to Me” covers the impact that generalized myasthenia gravis (gMG), a rare neuromuscular disease, has on patients and their loved ones. The docuseries won a bronze Pharma Lion in 2021, an award that celebrates creative work that brings science and innovation to life. The docuseries is hosted on MG United, an online platform that offers resources, education, and more for the MG community. At argenx, we focus on listening to and learning from people with rare diseases so that we can better address their needs and aspirations.

We build our culture from the collective power of the team and the knowledge that together we are better. Each individual’s performance contributes to the broader purpose, so we lift each other to higher levels while holding each other accountable.

We look forward to working with you on our ongoing quest to reach patients through immunology innovation and hope you are as excited as we are to discover together.

## Our Core Values

Since our founding, we have built a reputation of consistent execution, hard work, and integrity on our path to bring immunology breakthroughs to the patients who need them.

The name “argenx” comes from the story of the Argonauts, the first story on record to recognize the power of the team rather than individual heroes. The Argonauts set out in a small boat on a wide ocean to bring back the golden fleece, a seemingly impossible task. Alone, each of these individuals could not have succeeded, but when banded together could achieve the unthinkable.

By joining argenx, we are all choosing to join the adventure, to be part of this team looking to build the

next great integrated immunology company that is rooted in science, data-based in our decision-making, and always focused on the patient. Our cultural pillars emerged from our Founders, who were building the company they wanted to work for. As we grow, we have the same choice—to earn our reputation as the global company we want to be, and to live by the values that have been embedded in the fabric of everything we do.

Learn more about us and what we believe at [argenx.com](https://argenx.com).

Our values guide our business relationships and collaborations both within and beyond our walls. We thrive on curiosity and trust in the power of the team to help us identify immunology breakthroughs.



### Innovation

#### Our Core Mission

We live to innovate—and do so at every step



### Co-creation

#### We Create Through Collaboration

We trust in the power of the team and know that together we are better



### Empowerment

#### We Share in Our Joint Purpose

Our people are our most valuable asset



### Excellence

#### We Have a Quality Culture

We want to do things right the first time and prioritize patient safety



### Humility

#### The Heart of Our Organization

We want to handle successes and challenges gracefully and learn from both



# Our Fellowship Leadership

## Get to Know the People Behind the Program



**Jay Seetharaman**  
LEAD

*Senior Director, Medical Information*

**BSc, Mathematics and Computer Science,  
Madras University, India**



**Ashwin Kittur, MSPH, MBA,**  
LEAD

*Head of Shared Medical Services, Scientific Communications/Medical Information/ Medical Operations*

**BSc, Biochemistry, University of Ottawa  
MSPH, University of North Carolina at Chapel Hill  
MBA, Zicklin School of Business, City University of New York**



**Brant Hubbard, PhD**  
LEAD

*Director, Head of Publications,  
Scientific Communications*

**BS, Biochemistry and Biological/Biosystems Engineering, University of Nebraska at Lincoln  
PhD, Biochemistry & Molecular Biology, Boston University**



**Soheil Chavoshi, MS**  
LEAD

*Senior Director, Scientific Communication*

**BSc, Applied Health Sciences, University of Waterloo  
MS, Clinical Biostatistics & Epidemiology, McMaster University**



**Michael Yeakey, PharmD**  
PRECEPTOR

*Associate Medical Director, Hematology*

**PharmD, Purdue University**



**Saloni Patel, PharmD**  
PRECEPTOR

*Associate Director, US Medical Promotional Review*

**BSc, Pharmacy, Northeastern University  
PharmD, Northeastern University**

## Fellowship Program Director



**Sunil B. Mehta, PharmD**


*Vice President, Head of US Medical Affairs*

**PharmD, Ernest Mario School of Pharmacy at Rutgers University**

Sunil completed his PharmD from Ernest Mario School of Pharmacy at Rutgers University, followed by a Medical Affairs and Medical Strategy postdoctoral fellowship in cardiology and infectious diseases at Bristol Myers Squibb, where he was involved in developing medical strategy and training for medical affairs and commercial organizations.

# Medical Affairs Fellowship Position

During the 2-year Medical Affairs Fellowship, the Fellow will gain critical experience in key Medical Affairs functional areas:



To ensure an enriching experience, the sequencing of rotations is subject to the chosen Fellow's interests and business opportunities.

## Fellowship Overview

US Medical Affairs plays a fundamental role in providing scientific leadership in launching and sustaining the life cycle of new therapies, creating and disseminating scientific communication, and providing field-based medical knowledge to the healthcare community. argenx is proud to offer wide-ranging and unique experiences in US Medical Affairs, with a focus on autoimmune diseases.

## Fellowship Goal

The key goal of this Fellowship is to gain relevant experience working cross-functionally within different departments and to gain a deeper understanding of the roles and strategies within US Medical Affairs.

## Program Objectives

The Fellow will gain proficiency in key areas of Medical Affairs, such as:

- Gaining invaluable experience focusing on novel and innovative therapies within immunology like efgartigimod alfa, a first-in-class FcRn antagonist, and navigating the implementation of these therapies through clinical trial development, regulatory body approval, and final commercial availability of the drug for patients
- Introduction to Medical Affairs, the structure of the team, and how they operate
- Scientific Communications—related experiences including communication strategy development and implementation including manuscripts, posters, oral presentations, congress management, and scientific communications platform development
- Medical Information—related experiences including content creation, scientific training, review of promotional and medical materials, and call center management
- Attending scientific conferences including presentations, educational sessions, and symposia and reporting key findings
- Engagement with cross-functional and cross-regional teams, including field medical, regulatory, commercial, health economics and outcomes research (HEOR), legal, clinical development, and corporate communications, among many others
- Launch experience, including US-, EU-, and Japan-related launches

# Fellowship Breakdown



**Neethu Saji, PharmD**  
First-Year Fellow

*US Medical Affairs*

**St Joseph's University**  
**Philadelphia College of Pharmacy**

## Year 1

### Medical Information Rotation

- Medical Information is responsible for providing scientifically accurate, compliant, relevant, and timely product information to HCPs through live discussions and written responses, thereby allowing the HCP to make an informed risk-benefit decision regarding the appropriate use of argenx's marketed products
- Length of rotation: 10 months
- Rotation Liasons: Jay Seetharaman, Michael Sevigny, Marilla Pender-Cudlip
- Potential experiences:
  - Learn about call center operations, manage call center vendors, and work with the Safety and Quality teams
  - Create medical information content in a componentized fashion, including response documents and FAQs
  - Get an overview of the medical review process within different committees
  - Learn and assist in globalization and localization of content across different regions
  - Get an overview of the scientific training process within Medical Affairs

### Elective Rotation

This rotation will be based on the Fellow's career aspirations and argenx business opportunities. Some options may include:

- Field medical
- Marketing
- HEOR
- Clinical Development

**Length of rotation: 2 months**

## Year 2

### Scientific Communications Rotation

- The Scientific Communications team encompasses the development and delivery of programs, publications, symposia, continuing medical education (CME), and more that facilitate scientific exchange among doctors, pharmacists, nurses, and other stakeholders within the space, including payers, formulary decision-makers, and patient advocacy groups. The Fellow will be at the forefront of scientific communication and exchange, an invaluable experience for an aspiring specialist in Medical Affairs
- Length of rotation: 10 months
- Rotation Liasons: Soheil Chavoshi, Brant Hubbard
- Potential experiences:
  - Assist in the execution of strategic publication planning, including providing support for the development of posters, abstracts, oral presentations, manuscripts, and content for medical science liaisons (MSLs)
  - Collaborate with key internal stakeholders to plan congress engagement strategy, including medical booths and scientific symposia
  - Travel to and participation in scientific congresses, including competitive intelligence insight gathering and strategy operational execution

### Elective Rotation

This rotation will be based on the Fellow's career aspirations and argenx business opportunities. Some options may include:

- Field medical
- Marketing
- HEOR
- Clinical Development

**Length of rotation: 2 months**



### Rutgers Pharmaceutical Industry Fellowship Program

Ernest Mario School of Pharmacy  
Rutgers, The State University of New Jersey

#### Program History

In 1984, at Rutgers, The State University of New Jersey, the Ernest Mario School of Pharmacy and two pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically-trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program grew significantly and expanded to include 27 companies within the pharmaceutical and biopharmaceutical industry and approximately 350 Fellows.

In 2002, Dr. Ernest Mario generously provided an endowment to establish the [Institute for Pharmaceutical Industry Fellowships](#) to enhance and promote the role of pharmacists in industry through the RPIF Program.

The Institute staff members:

- provide leadership and administrative support
- promote quality, communication, scholarly activity, and professional development
- arrange specialized Fellowship training opportunities within the pharmaceutical and biopharmaceutical industry.

In 2018, our Program expanded to offer interdisciplinary Fellows' training by adding select physician Fellowship opportunities to our well-established program.

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Professor II of the Ernest Mario School of Pharmacy, Dr. Carolyn Seyss, the Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.

The RPIF Program Certificate is now associated with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**. Well over 1,500 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.



**Joseph A. Barone,**  
Pharm.D., F.C.C.P.  
Dean and Professor II  
Ernest Mario School of  
Pharmacy  
Rutgers University



**Carolyn Seyss,**  
Pharm.D., RUCIF  
Fellowship Director  
Institute for Pharmaceutical Industry  
Fellowships  
Ernest Mario School of Pharmacy



**Michael Toscani,**  
Pharm.D.  
Research Professor,  
Fellowship Director Emeritus  
Institute for Pharmaceutical  
Industry Fellowships



Connect with us on social  
media: @RutgersFellow



### Key Program Features

The Rutgers Pharmaceutical Industry Fellowship Program **FOSTERs** the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through key program features:

**F**

**Family of Leading Companies** – Partners include several of the top global pharmaceutical and biopharmaceutical companies and offer large to small company environments.

**O**

**Outstanding Alumni Track Record** – Well over 1,500 alumni hold prominent positions at many leading companies, including VP and C-suite levels.

**S**

**Strong Network** — Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.

**T**

**Trusted and Proven Since 1984** — the Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry for pharmacists as future leaders.

**E**

**Enhanced Career Development** – Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.

**R**

**Rigorous Academic Component** – Rutgers affiliation provides academic and professional development opportunities.

Rutgers, The State University of New Jersey, with over 67,000 students in its three campuses, is one of the major state university systems in the United States. The New Jersey College of Pharmacy was founded in 1892 and was incorporated into the University in 1927. The [Ernest Mario School of Pharmacy \(EMSOP\)](#) is part of Rutgers Biomedical and Health Sciences (RBHS), the only state school of pharmacy in New Jersey, with approximately 1,350 students in its Doctor of Pharmacy degree program. The Rutgers EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey. Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, the EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

### Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the partner companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. The dynamic forum of PDD provides an opportunity for open discussion and debate among Fellows, Rutgers faculty, and company Preceptors. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.



Connect with us on social  
media: @RutgersFellow



**Application Process and Eligibility Requirements:**

Pharmacy Fellows for the Rutgers Pharmaceutical Industry Fellowship Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy degree from an ACPE-accredited institution before July 1 of the fellowship term.

**How to Apply:**

The RPIF Program is highly competitive. Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as October 6, 2023 by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials **must be submitted electronically to the RPIF Website** per instructions on the site.

**Your Letter of Intent & Letters of Recommendation should be addressed to:**

Joseph A. Barone, Pharm.D., F.C.C.P.  
Dean and Professor II  
Ernest Mario School of Pharmacy  
Rutgers, The State University of New Jersey  
160 Frelinghuysen Road  
Piscataway, NJ 08854-8020

**Alliance of Industry Fellowship Associates Fellowship Offers**

Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, AIFA exists to promote a common aspect of each of our program's cultures by supporting a consensus first offer date of December 13, 2023 for all fellowship candidates.

We hope that other academic and non-academic Fellowship Programs will respect this timeline to allow for best program fit for candidates.

Required Items	Submit by
Application with short-answer questions	October 13th
Letter of Intent (LOI)	October 13th
Curriculum Vitae (CV)	October 13th
Letters of Recommendation (LORs)	December 1st



Connect with us on social  
media: @RutgersFellow

# RUTGERS

Institute for Pharmaceutical  
Industry Fellowships



Rutgers/argenx Pharmaceutical Industry Fellowship Program 2024 | [argenx.com](https://argenx.com)